Search clinical trials for: Pomalidomide

Total 264 results

AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Montefiore... and other collaborators

Active, not recruiting

Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

Human Immunodeficiency Virus 1 Positive | Skin Kaposi Sarcoma

Uganda, Kenya, Malawi
The First Affiliated Hospital of Soochow University

Recruiting

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Diffuse Large B Cell Lymphoma

China
Qilu Pharmaceutical Co., Ltd.

Active, not recruiting

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Recurrent or Refractory

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)

Multiple Myeloma

United States, Belgium, United Kingdom, France, Australia
OHSU Knight Cancer Institute
Sanofi; Oregon Health and Science University

Active, not recruiting

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Celgene

Completed

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS)

Multiple Myeloma

Netherlands, Spain, Belgium, Austria, Switzerland, Italy, Germany, France, Ireland, United Kingdom, Denmark, Finland, Portugal, Turkey, Poland, Estonia, Greece, Norway, Slovakia, Sweden
Incyte Corporation

Terminated

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Metastatic Cancer | Solid Tumors | Advanced Malignancies

United States
Poitiers University Hospital
Sanofi; Celgene; Amgen; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Recurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCL

United States
Swiss Group for Clinical Cancer Research

Terminated

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (OptiPOM)

Refractory Multiple Myeloma

Switzerland
Celgene Corporation

Completed

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
SOFAR S.p.A.

Completed

Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA®

Wound Healing Disorder

Italy
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

China
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi

Recruiting

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (IsAMYP)

AL Amyloidosis

France
Amgen

Terminated

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia, Japan, Germany, Netherlands, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Multiple Myeloma | Relapsed/Refractory

United States
AbbVie

Terminated

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Germany, Spain
Samsung Medical Center

Recruiting

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone (KMM2002)

Multiple Myeloma

Korea, Republic of
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Korea, Republic of, Italy, Taiwan, China, Germany, Israel, Turkey, Japan, France, United Kingdom, Brazil, Spain, Czechia, Poland, Belgium, Greece, Netherlands
AbbVie

Terminated

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Germany, Israel, Japan, Spain
Celgene

Completed

Food Effect and CYP1A2 Induction Study in Healthy Subjects

Healthy Volunteers

United States
Takeda

Completed

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

Diabetes Mellitus, Type 2

Japan
European Myeloma Network
University of Turin, Italy

Completed

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (CPD)

Multiple Myeloma

Italy
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
Amgen

Terminated

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Jin Lu, MD

Recruiting

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

Systemic Amyloidosis

China
GlaxoSmithKline

Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Multiple Myeloma

China, Korea, Republic of, Australia, Italy, Spain, United States, Brazil, Czechia, France, Germany, Greece, Israel, Japan, New Zealand, Poland, Russian Federation, Turkey, United Kingdom
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients (DPd)

Multiple Myeloma | Deletion 17P Syndrome

Italy
Alliance Foundation Trials, LLC.
Celgene; Janssen, LP

Withdrawn

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
Criterium, Inc.
Celgene Corporation; Amgen

Terminated

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Recruiting

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Multiple Myeloma | Aging | Relapse | Co-morbidity | Refractory

United States
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

AL Amyloidosis | Amyloid | Refractory AL Amyloidosis

United States
Pharmacyclics LLC.
Celgene Corporation

Terminated

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Czechia, Germany, Greece
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
Massachusetts General Hospital
Sanofi; GlaxoSmithKline

Not yet recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Cancer

United States
University of Chicago
GlaxoSmithKline; Amgen

Recruiting

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Multiple Myeloma | Relapse Multiple Myeloma

United States
Hellenic Society of Hematology
GlaxoSmithKline

Not yet recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, Germany, Belgium, Denmark, Greece, France, United States, Ukraine, Poland
European Myeloma Network
Karyopharm Therapeutics Inc

Recruiting

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Multiple Myeloma

Spain, United States, Germany, Netherlands, Greece, France, Italy
University of Colorado, Denver
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse

United States
Celgene

Active, not recruiting

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Multiple Myeloma

United States, Canada, Japan, Puerto Rico
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
Sanofi

Completed

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)

Plasma Cell Myeloma

United States
AbbVie

Recruiting

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, Taiwan
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Not yet recruiting

Marizomib Central Nervous System (CNS)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Andrew Yee, MD
Janssen Research & Development, LLC; Amgen

Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Multiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in Relapse

United States

Search clinical trials for: Pomalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations